retatrutide mechanism triple agonist gip glp-1 glucagon Beyond GLP-1: Retatrutide's triple-agonist (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Frontiers | Glucagon-like peptide-1 and

The CHMP adopted a new pharmaceutical form associated with a new route of administration, tablets for oral use, in four new strengths (1.5 mg, 4 mg, 9 mg and 25 mg)

155 However, whether this can be extrapolated to other CMRFs, and whether there is a pharmacoeconomic imperative, needs further clarification

Zepbound hit 77,590 new prescriptions in the United States for the week ending March 8, 2024, beating rival Wegovy

E.KeiflinR.BoivinJ

Sources: Veniant et al., Nat Metab, 2024

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials